Healthcare Industry News: osteoarthritis
News Release - November 13, 2006
Anika Therapeutics Appoints Constance Garrison as Vice President of Regulatory and Clinical AffairsSeasoned Executive Brings More Than 20 Years Experience to Company
WOBURN, Mass., Nov. 13 (HSMN NewsFeed) -- Anika Therapeutics, Inc. (Nasdaq: ANIK ) today announced that Constance H. Garrison has joined the Company as Vice President of Regulatory and Clinical Affairs. Garrison comes to Anika from German-based Miltenyi Biotec, Inc., where she had been vice president, Regulatory Affairs for the past three years. In her role at Miltenyi Biotec, she also led the company's U.S. quality assurance team.
"Connie brings more than two decades of broad experience in regulatory affairs, quality assurance, clinical affairs and product development to Anika," said Charles H. Sherwood, Ph.D., Anika's president and chief executive officer. "We look forward to leveraging Connie's expertise as we seek to develop a series of cosmetic tissue augmentation line extensions and to enhance our pipeline of products to address a range of joint health indications. We welcome Connie to our team and look forward to her contributions."
Prior to her tenure at Miltenyi, Garrison served for seven years at Massachusetts-based BioTransplant Incorporated/Eligix, Inc., advancing to the position of vice president of Regulatory Affairs and Quality Assurance. She began her career at Coulter Corporation in Florida, where she served in roles of increasing responsibility in R&D, marketing and product development.
Garrison received an M.B.A. in marketing from Barry University in Florida and a B.A. in natural sciences from Doane College in Crete, Nebraska. She holds several patents and received her Regulatory Affairs Certification from the Regulatory Affairs Professional Society in 1998.
About Anika Therapeutics, Inc.
Headquartered in Woburn, Mass., Anika Therapeutics, Inc. (http://www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika products include OrthoVisc®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek, and Hyvisc®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc. Anika manufactures Amvisc(TM) and Amvisc Plus(TM), HA viscoelastic products for ophthalmic surgery. It also produces STAARVISC(TM)-II, which is distributed by STAAR Surgical company and Shellgel(TM) for Cytosol Ophthalmics, Inc.
Statements in this press release may be considered "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements, including Anika's plans to seek to develop a series of cosmetic tissue augmentation line extensions and to enhance its pipeline of products to address a range of joint health indications, are based on management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially. Such factors that could cause actual results to differ materially from any forward-looking statements made by the Company include, among others, the company's research and product development efforts and their relative success, the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, and receive FDA or other regulatory approvals of its products. Further information on factors that could affect Anika's financial results is included in the Company's filings with the Securities and Exchange Commission including the company's Annual Report on Form 10-K for the year ended December 31, 2005, and its Quarterly Report on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2006 and Current Reports on Form 8-K, as well as those described in the company's other press releases and SEC filings.
Source: Anika Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.